ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*J2.0.21 - 2999001/03634461CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120230802W173deBibliographieenBibliographyfrBibliographieEP18729565.4201805042019120420201222enenen1730552720170509EP2023080220233120200415202016202307052023272022121520230802202331A61K 38/08 20190101AFI20181116BHEP A61K 38/45 20060101ALI20181116BHEP A61K 39/00 20060101ALI20181116BHEP A61P 35/00 20060101ALI20181116BHEP C07K 7/06 20060101ALI20181116BHEP A61K 38/08 20130101 LI20171013BHEP A61K2300/00 20130101 LI20171013BHEP A61K 39/0011 20130101 LI20171013BHEP A61K2300/00 20130101 LI20171013BHEP A61K 38/08 20130101 FI20201222RHEP A61K 38/45 20130101 LI20171013BHEP A61K 39/0011 20130101 LI20171013BHEP C07K 7/06 20130101 LI20171013BHEP C12Y 207/07049 20130101 LI20171013BHEP A61P 35/00 20180101 LI20200327BHEP deIMPFSTOFF ZUR ABZIELUNG AUF EIN KRYPTISCHES TERT-EPITOP ZUR BEHANDLUNG VON LUNGENKREBS IN EINEM HLA-A*0201-POSITIVEN PATIENTEN, DER NIE ODER WENIGER GERAUCHT HATenVACCINE TARGETING A CRYPTIC TERT EPITOPE, FOR TREATING LUNG CANCER IN A HLA-A*0201-POSITIVE NEVER-SMOKER OR LIGHT-FORMER SMOKER PATIENTfrVACCIN CIBLANT UN ÉPITOPE TERT CRYPTIQUE, POUR LE TRAITEMENT DU CANCER DU POUMON CHEZ UN NON FUMEUR POSITIF AU HLA-A*0201 OU CHEZ UN PATIENT ANCIEN FUMEUR LÉGERWO-A2-2006/120038ELENI-KYRIAKI VETSIKA ET AL: "Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 2, 20 August 2011 (2011-08-20), pages 157-168, XP035005847, ISSN: 1432-0851, DOI: 10.1007/S00262-011-1093-4LAN QING ET AL: "Longer Telomere Length in Peripheral White Blood Cells Is Associated with Risk of Lung Cancer and the rs2736100 (CLPTM1L-TERT) Polymorphism in a Prospective Cohort Study among Women in China", PLOS ONE, vol. 8, no. 3, March 2013 (2013-03), XP055415765, ISSN: 1932-6203N. A. RIZVI ET AL: "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", SCIENCE, vol. 348, no. 6230, 3 April 2015 (2015-04-03), pages 124-128, XP055322846, ISSN: 0036-8075, DOI: 10.1126/science.aaa1348ZHANG TENGFEI ET AL: "The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis", ONCOTARGET, vol. 7, no. 45, 8 November 2016 (2016-11-08), pages 73068-73079, XP055415778,DOGAN SNJEZANA ET AL: "Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers", CLINICAL CANCER RESEARCH, vol. 18, no. 22, November 2012 (2012-11), pages 6169-6177, XP055415781,BUCCHERI G ET AL: "Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 32, no. 7, 1 June 1996 (1996-06-01), pages 1135-1141, XP027246652, ISSN: 0959-8049 [retrieved on 1996-06-01]TOMOHIRO TAMURA ET AL: "Specific organ metastases and survival in metastatic non-small-cell lung cancer", MOLECULAR AND CLINICAL ONCOLOGY, vol. 3, no. 1, 4 September 2014 (2014-09-04), pages 217-221, XP055497469, GR ISSN: 2049-9450, DOI: 10.3892/mco.2014.410KOSMATOPOULOS, Kostantinos (Kostas)1 Rue du Cardinal Lemoine75005 ParisFRMENEZ-JAMET, Jeanne27 B Rue de la Vanne92120 MontrougeFRKriptic Pharmaceuticals Limited102000079B170118EPB/VEMOne Spencer Dock North Wall QuayDublin 1IESantarelli100060587Tour Trinity 1 bis Esplanade de la Défense92035 Paris La Défense CedexFRALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTREP201806160920180504enWO201820646220181115201846